# Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

Study · id `cardio:ct-nct04072835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04072835](<https://clinicaltrials.gov/study/NCT04072835>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04072835

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1116 participants.

## Technical summary

Registry record NCT04072835. Non-randomized; no masking; primary purpose treatment. Start 2019-09-23 (actual); primary completion 2023-01-26 (actual). Results posted on 2024-05-23.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1116 participants (enrolled count; ClinicalTrials.gov record NCT04072835, source copy `cardio:ctgov-nct04072835-2024-05-23`, retrieved 2026-10-26)
- Started: 2019-09-23 (actual) (ClinicalTrials.gov record NCT04072835, source copy `cardio:ctgov-nct04072835-2024-05-23`, retrieved 2026-10-26)
- Primary completion: 2023-01-26 (actual) (ClinicalTrials.gov record NCT04072835, source copy `cardio:ctgov-nct04072835-2024-05-23`, retrieved 2026-10-26)
- Completion: 2023-01-26 (actual) (ClinicalTrials.gov record NCT04072835, source copy `cardio:ctgov-nct04072835-2024-05-23`, retrieved 2026-10-26)
- Results first posted: 2024-05-23 (ClinicalTrials.gov record NCT04072835, source copy `cardio:ctgov-nct04072835-2024-05-23`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; Canada; Colombia (ClinicalTrials.gov record NCT04072835, source copy `cardio:ctgov-nct04072835-2024-05-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04072835-2024-05-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
- Condition: Paroxysmal Supraventricular Tachycardia
- Intervention (Drug): Etripamil NS
- Lead sponsor: Milestone Pharmaceuticals Inc.
- Lead sponsor class: OTHER
- Collaborator: IQVIA Biotech
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: Milestone Pharmaceuticals Inc. (`cardio:org-milestone-pharmaceuticals-inc`)
- Registry lists this organization as a collaborator: IQVIA Biotech (`cardio:org-iqvia-biotech`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study (`cardio:pubmed-40931676`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Self-Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE-303 Study (`cardio:pubmed-41668514`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: da0d92ccb9d99370ebe0af185b930adcd7ba74b7eddde98550e92535f4e494ef
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
